Suppr超能文献

溴莫尼定和布林佐胺局部给药后在兔体内的眼内和全身药代动力学:固定复方制剂与单药制剂的比较

Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.

作者信息

Suzuki Gen, Kunikane Eriko, Shigemi Wakasa, Shinno Keisuke, Kozai Seiko, Kurata Masaaki, Kawamura Akio

机构信息

Research & Development Division, Senju Pharmaceutical Co., Ltd ., Osaka, Japan.

出版信息

Curr Eye Res. 2021 Mar;46(3):380-386. doi: 10.1080/02713683.2020.1800046. Epub 2020 Aug 12.

Abstract

AIM

The aim of this study was to compare the ocular and systemic absorption of brimonidine (BMD) and brinzolamide (BZM) in rabbits after the topical administration of a fixed-combination ophthalmic suspension of 0.1% BMD tartrate and 1% BZM (FCBB) with that after the administration of the respective single-drug formulations.

MATERIALS AND METHODS

Ocular and systemic drug absorption was estimated by determining BMD and BZM concentrations in the aqueous humor, retina/choroid, vitreous body, and blood/plasma by liquid chromatography/tandem mass spectrometry after the administration of FCBB, 0.1% BMD tartrate ophthalmic solution (0.1% BMD), or 1% BZM ophthalmic suspension (1% BZM) to rabbits.

RESULTS

In concomitant administration, instilling 0.1% BMD and 1% BZM successively without interval lowered aqueous humor concentrations of both drugs compared to those observed with a 5-min interval. After FCBB administration, BMD and BZM concentrations in the aqueous humor were comparable with those observed after the administration of 0.1% BMD and 1% BZM, whereas BMD concentrations in posterior ocular tissues were equal to or higher than those observed after 0.1% BMD. Plasma BMD concentrations following the administration of FCBB were 0.8-fold lower than those after 0.1% BMD; no remarkable differences were observed in blood BZM concentrations for both formulations.

CONCLUSIONS

FCBB achieved drug distribution in the aqueous humor and systemic exposure that were comparable to those for the single-drug formulations. The viscosity of FCBB may increase BMD distribution in the retina/choroid. The administration interval affects ocular drug absorption with the concomitant administration of 0.1% BMD and 1% BZM, which can be overcome by using the fixed-combination of both drugs.

摘要

目的

本研究旨在比较0.1%酒石酸溴莫尼定(BMD)和1%布林佐胺(BZM)的固定组合眼用混悬液(FCBB)与各自单药制剂局部给药后,家兔眼内及全身对BMD和BZM的吸收情况。

材料与方法

通过液相色谱/串联质谱法测定家兔分别给予FCBB、0.1%酒石酸溴莫尼定眼用溶液(0.1%BMD)或1%布林佐胺眼用混悬液(1%BZM)后房水、视网膜/脉络膜、玻璃体及血液/血浆中BMD和BZM的浓度,以评估眼内及全身药物吸收情况。

结果

联合给药时,0.1%BMD和1%BZM连续无间隔滴注与间隔5分钟滴注相比,两种药物的房水浓度均降低。给予FCBB后,房水中BMD和BZM的浓度与给予0.1%BMD和1%BZM后观察到的浓度相当,而后部眼组织中BMD的浓度等于或高于给予0.1%BMD后观察到的浓度。给予FCBB后血浆中BMD的浓度比给予0.1%BMD后低0.8倍;两种制剂的血液中BZM浓度未观察到显著差异。

结论

FCBB在房水中的药物分布和全身暴露与单药制剂相当。FCBB的粘度可能会增加BMD在视网膜/脉络膜中的分布。给药间隔会影响0.1%BMD和1%BZM联合给药时的眼内药物吸收,而使用两种药物的固定组合可以克服这一问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验